Please login to the form below

Not currently logged in
Email:
Password:

disease progression

This page shows the latest disease progression news and features for those working in and with pharma, biotech and healthcare.

FDA green lights BMS’ multiple myeloma combo

FDA green lights BMS’ multiple myeloma combo

The results showed the combination could cut the risk of myeloma progression by 46% compared to Pomalyst and dexamethasone alone (Pd) This also demonstrated that the combination achieved an overall response ... BMS' Joseph Eid. “Empliciti plus

Latest news

  • FDA clears first-line use for J&J’s myeloma drug Darzalex FDA clears first-line use for J&J’s myeloma drug Darzalex

    the risk of disease progression or death by 50% in these patients. ... J&J is also carrying out mid-stage testing of Darzalex even further up the treatment chain in ‘smouldering’multiple myeloma, which is a precursor to full-blown disease that can

  • Pfizer claims rapid FDA nod for Lorbrena Pfizer claims rapid FDA nod for Lorbrena

    Lorbrena can also be used in patients who have seen disease progression on Roche’s Alecensa and Novartis’Zykadia. ... Follow-up ALK inhibitors are important in this treatment pathway, as many experience tumour progression after initial ALK inhibitor

  • Novartis gains label boost for Cosentyx Novartis gains label boost for Cosentyx

    The boost was based on 24-week structural disease progression data from FUTURE 5, which became the largest phase 3 study for a biologic conducted in PsA to date. ... no radiographic disease progression at 24 weeks.

  • Novartis claims a rare win at ESMO for PI3K inhibitor class Novartis claims a rare win at ESMO for PI3K inhibitor class

    The results of the SOLAR-1 trial showed that giving alpelisib (BYL719) alongside AstraZeneca’s venerable product Faslodex (fulvestrant) improved progression-free survival (PFS) in patients with hormone ... months for patients receiving Faslodex alone

  • Encouraging data for GenSight’s blinding retinal disease gene therapy Encouraging data for GenSight’s blinding retinal disease gene therapy

    Encouraging data for GenSight’ s blinding retinal disease gene therapy. Better results after April's setback. ... The level of sustained improvement in both visual acuity and low-contrast sensitivity, and the sustained preservation of retinal ganglion

More from news
Approximately 1 fully matching, plus 243 partially matching documents found.

Latest Intelligence

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    stop or reverse disease progression. ... Explain to study subjects and caregivers they can’t expect improvements of PD symptoms, although they may benefit from a slower disease progression over time.

  • No incentive for a cure No incentive for a cure

    to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to. ... Curative therapies have the potential to offset

  • A quest for innovative solutions A quest for innovative solutions

    disease progression. ... It is important that patients can see the value in tracking their disease.

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinson’s house'

    But this elegant home, surrounded by manicured lawns, is wired to beat the scourge of Parkinson’s disease. ... To show the stopping of disease progression can take a couple of years and that is a long time to conduct a clinical trial, so we hope we can

  • Accelerating innovation Accelerating innovation

    The new trial of previously untreated patients with advanced RCC showed a 52% reduction in the rate of disease progression or death compared to Sutent, with Cabometyx showing median progression-free

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

  • PatientsLikeMe names Jason Johnson as head of R&D PatientsLikeMe names Jason Johnson as head of R&D

    Johnson will lead the company's research, data science and informatics teams, which focus on analysing and merging patient-reported data and other data types to develop models of disease progression ... and generate new insights about disease, treatments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics